Skip to content

Syndax Pharmaceuticals SNDX Allowance for credit losses

Allowance for credit losses at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$916.75K
Mercury Systems logo
Mercury SystemsMRCY
-$28K-122%
Rumble, Inc. logo
Rumble, Inc.RUM
$177.43K-25.6%
Paymentus Holdings logo
Paymentus HoldingsPAY
$160K+231%
Aehr Test Systems logo
Aehr Test SystemsAEHR
$0
Sezzle logo
SezzleSEZL
$6.86M+73.3%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.74B+95.0%
Enterprise value$1.96B+84.0%
P/S-12.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForOtherCreditLosses.

The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's allowance for credit losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's allowance for credit losses?
Syndax Pharmaceuticals (SNDX) reported allowance for credit losses of $916.75K in Q4 2025.
What does allowance for credit losses mean?
This represents the estimated expense recognized to account for potential uncollectible receivables or other financial assets. It serves as a buffer against credit risk and reflects management's assessment of counterparty default probability.